Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Background - This detailed analysis further characterizes the safety profile of talazoparib plus enzalutamide in the ongoing randomized, phase III TALAPRO-2 study in patients with metastatic castration-resistant prostate cancer (mCRPC). In both the all-comers and homologous recombination repair (HRR...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2024
|
| In: |
European journal of cancer
Year: 2024, Jahrgang: 213, Pages: 1-9 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2024.115078 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2024.115078 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804924012097 
|
| Verfasserangaben: | Arun A. Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert J. Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D. Shore, Curtis Dunshee, Joan Carles, Andre P. Fay, Xun Lin, Liza DeAnnuntis, Nicola Di Santo, Michael A. Zielinski, Neeraj Agarwal |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1950645398 | ||
| 003 | DE-627 | ||
| 005 | 20260130085410.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2024.115078 |2 doi | |
| 035 | |a (DE-627)1950645398 | ||
| 035 | |a (DE-599)KXP1950645398 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Azad, Arun |e VerfasserIn |0 (DE-588)1388439468 |0 (DE-627)1950646327 |4 aut | |
| 245 | 1 | 0 | |a Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer |b safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study |c Arun A. Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert J. Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D. Shore, Curtis Dunshee, Joan Carles, Andre P. Fay, Xun Lin, Liza DeAnnuntis, Nicola Di Santo, Michael A. Zielinski, Neeraj Agarwal |
| 246 | 3 | 0 | |a two |
| 264 | 1 | |c December 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 20. Oktober 2024, Artikelversion: 31. Oktober 2024 | ||
| 500 | |a Gesehen am 30.01.2026 | ||
| 520 | |a Background - This detailed analysis further characterizes the safety profile of talazoparib plus enzalutamide in the ongoing randomized, phase III TALAPRO-2 study in patients with metastatic castration-resistant prostate cancer (mCRPC). In both the all-comers and homologous recombination repair (HRR)-deficient populations, talazoparib plus enzalutamide significantly improved radiographic progression-free survival compared with placebo plus enzalutamide. - Methods - The talazoparib plus enzalutamide safety populations in TALAPRO-2 included 398 patients from cohort 1 (all-comers, unselected for HRR gene alterations) and 198 patients from the combined HRR-deficient population (patients from the all-comers population with HRR gene alterations plus subsequently enrolled patients with HRR gene alterations; cohort 2). Patients received talazoparib 0.5 mg (0.35 mg, moderate renal impairment) and enzalutamide 160 mg once daily. Safety analyses evaluated common treatment-emergent adverse events (TEAE), their type, severity, timing, seriousness, and relationship to study treatment. - Results - In the all-comers (n = 398) and HRR-deficient populations (n = 198), all-cause grade 3/4 (G3/4) TEAEs with talazoparib plus enzalutamide were reported in 71.9 % and 66.2 % of patients, respectively. Most common G3/4 hematologic TEAEs were anemia (46.7 % and 40.9 %, respectively), neutropenia (18.3 % and 18.7 %), and thrombocytopenia (7.3 % and 7.1 %). Median time to event was 3.3 and 3.3 months for G3/4 anemia, 2.3 and 2.3 months for G3/4 neutropenia, and 2.3 and 1.5 months for G3/4 thrombocytopenia. Maximum hemoglobin reduction occurred after 13 and 15 weeks of treatment. 18.8 % and 10.1 % of patients discontinued talazoparib. TEAEs were managed with dose interruption (62.1 % and 57.6 %), reduction (52.8 % and 52.0 %), hematologic supportive care (13.1 % and 10.6 %), and packed red blood cell transfusions (39.2 % and 35.9 %). - Conclusion - Talazoparib plus enzalutamide had a generally manageable safety profile in patients with mCRPC within the all-comers and the HRR-deficient populations. - ClinicalTrials.gov Identifier - NCT03395197 | ||
| 650 | 4 | |a Controlled clinical trials, Randomized | |
| 650 | 4 | |a Poly(ADP-ribose) Polymerase inhibitors | |
| 650 | 4 | |a Prostatic neoplasms, Castration-resistant | |
| 650 | 4 | |a Safety | |
| 700 | 1 | |a Fizazi, Karim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Matsubara, Nobuaki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Saad, Fred |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Giorgi, Ugo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Joung, Jae Young |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fong, Peter C. C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jones, Robert J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zschäbitz, Stefanie |d 1983- |e VerfasserIn |0 (DE-588)1037698827 |0 (DE-627)75589894X |0 (DE-576)391727206 |4 aut | |
| 700 | 1 | |a Oldenburg, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shore, Neal D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dunshee, Curtis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carles, Joan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fay, Andre P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lin, Xun |e VerfasserIn |4 aut | |
| 700 | 1 | |a DeAnnuntis, Liza |e VerfasserIn |4 aut | |
| 700 | 1 | |a Di Santo, Nicola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zielinski, Michael A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Agarwal, Neeraj |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 213(2024) vom: Dez., Artikel-ID 115078, Seite 1-9 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study |
| 773 | 1 | 8 | |g volume:213 |g year:2024 |g month:12 |g elocationid:115078 |g pages:1-9 |g extent:9 |a Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study |
| 787 | 0 | 8 | |i Ergänzung |a Azad, Arun |t Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078] |d 2026 |w (DE-627)1950646637 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2024.115078 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804924012097 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260130 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1037698827 |a Zschäbitz, Stefanie |m 1037698827:Zschäbitz, Stefanie |d 910000 |d 910100 |d 50000 |e 910000PZ1037698827 |e 910100PZ1037698827 |e 50000PZ1037698827 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 9 | ||
| 999 | |a KXP-PPN1950645398 |e 4865580190 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"December 2024","dateIssuedKey":"2024"}],"note":["Online verfügbar: 20. Oktober 2024, Artikelversion: 31. Oktober 2024","Gesehen am 30.01.2026"],"title":[{"subtitle":"safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study","title_sort":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer","title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"part":{"pages":"1-9","year":"2024","extent":"9","text":"213(2024) vom: Dez., Artikel-ID 115078, Seite 1-9","volume":"213"},"titleAlt":[{"title":"EJC online"}],"language":["eng"],"disp":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 studyEuropean journal of cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press","dateIssuedDisp":"1992-"}],"pubHistory":["28.1992 -"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"id":{"eki":["266883400"],"issn":["1879-0852"],"zdb":["1468190-0"]},"recId":"266883400"}],"recId":"1950645398","name":{"displayForm":["Arun A. Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert J. Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D. Shore, Curtis Dunshee, Joan Carles, Andre P. Fay, Xun Lin, Liza DeAnnuntis, Nicola Di Santo, Michael A. Zielinski, Neeraj Agarwal"]},"physDesc":[{"noteIll":"Illustrationen","extent":"9 S."}],"id":{"eki":["1950645398"],"doi":["10.1016/j.ejca.2024.115078"]},"person":[{"role":"aut","given":"Arun","display":"Azad, Arun","family":"Azad"},{"display":"Fizazi, Karim","family":"Fizazi","role":"aut","given":"Karim"},{"display":"Matsubara, Nobuaki","family":"Matsubara","role":"aut","given":"Nobuaki"},{"display":"Saad, Fred","family":"Saad","given":"Fred","role":"aut"},{"given":"Ugo","role":"aut","family":"De Giorgi","display":"De Giorgi, Ugo"},{"display":"Joung, Jae Young","family":"Joung","role":"aut","given":"Jae Young"},{"role":"aut","given":"Peter C. C.","display":"Fong, Peter C. C.","family":"Fong"},{"display":"Jones, Robert J.","family":"Jones","role":"aut","given":"Robert J."},{"family":"Zschäbitz","display":"Zschäbitz, Stefanie","given":"Stefanie","role":"aut"},{"role":"aut","given":"Jan","display":"Oldenburg, Jan","family":"Oldenburg"},{"given":"Neal D.","role":"aut","family":"Shore","display":"Shore, Neal D."},{"role":"aut","given":"Curtis","family":"Dunshee","display":"Dunshee, Curtis"},{"given":"Joan","role":"aut","family":"Carles","display":"Carles, Joan"},{"role":"aut","given":"Andre P.","family":"Fay","display":"Fay, Andre P."},{"role":"aut","given":"Xun","family":"Lin","display":"Lin, Xun"},{"given":"Liza","role":"aut","display":"DeAnnuntis, Liza","family":"DeAnnuntis"},{"family":"Di Santo","display":"Di Santo, Nicola","given":"Nicola","role":"aut"},{"display":"Zielinski, Michael A.","family":"Zielinski","role":"aut","given":"Michael A."},{"display":"Agarwal, Neeraj","family":"Agarwal","given":"Neeraj","role":"aut"}],"language":["eng"]} | ||
| SRT | |a AZADARUNFITALAZOPARI2024 | ||